Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

PET/TC con 18F-fluciclovina en mieloma múltiple

10 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Un ensayo de fase II que evalúa la PET/TC con 18F-fluciclovina en el mieloma múltiple

Background:

Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier.

Objective:

To find out if the radiotracer 18F-fluciclovine (a substance injected into the blood during imaging scans) is better at detecting MM than the one (18F-FDG) currently used for this purpose.

Eligibility:

Adults aged 18 years or older with MM. The MM may be newly diagnosed (NDMM); or it may have returned or failed to respond after at least 1 prior line of treatment (RRMM).

Design:

Participants will be screened. They will have blood tests. They will have a positron emission tomography (PET) or computed tomography (CT) scan using 18F-FDG. The radiotracer will be injected into a vein. Then participants will lie on a table while the PET/CT scan takes images of their body.

All participants will have 3 study visits. During each visit they will have:

Two PET/CT scans. One with 18F-FDG, one with 18F-fluciclovine.

An optional magnetic resonance imaging scan.

A bone marrow biopsy. An area on the hip will be numbed; a needle will be inserted to draw out a sample of the soft tissue from inside the bone.

These tests may be spread over 30 days for each visit.

NDMM participants will have their second study visit 2 to 4 weeks after they complete their usual treatment for the disease. RRMM participants will have their second visit 6 months after their first.

All participants will have a third study visit after 5 years or when their disease progresses.

Descripción general del estudio

Descripción detallada

Background:

  • Multiple myeloma (MM) is an incurable malignancy of plasma cells that leads to destructive bone lesions, renal damage, anemia, and hypercalcemia. MM is the second most common hematologic malignancy. The American Cancer Society estimates that annually over 34,000 new cases of MM will occur in the U.S. and over 12,000 deaths due to MM in 2022.
  • Overall survival (OS) has improved significantly over the past 20 years with the development of proteasome inhibitors (PIs), immunomodulatory agents (IMiDs) and anti-CD38 monoclonal antibodies. However, despite these advances, patients ultimately relapse requiring multiple subsequent lines of therapy. As MM evolves, it generally becomes more refractory, and patients ultimately succumb to their disease.
  • With multiple lines of efficacious therapies, the correct early identification of relapsed disease is important to trigger initiation of a new line of therapy.
  • Limitations in conventional imaging highlight a need for molecular imaging agents with better sensitivity for detecting and measuring tumor burden to improve staging and treatment selection for patients with MM and plasma cell dyscrasias.
  • 18F-fluciclovine is a radionuclide approved by the FDA for evaluating suspected prostate cancer recurrence but has shown additional ability in detecting MM lesions.

Objective:

To determine the concordance between 18F-fluciclovine PET/CT and 18F-FDG PET/CT in participants with multiple myeloma

Eligibility:

  • Participants >= 18 years old

  • Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2

  • Participants must have a documented diagnosis of MM defined by the International Myeloma Working Group (IMWG) Criteria

  • Participants fit criteria for one of the following categories:

    • Newly diagnosed multiple myeloma (NDMM) without previous treatment (or within the first 3 cycles of front-line treatment)
    • Relapsed and/or Refractory multiple myeloma (RRMM) with at least 1 prior line of therapy

Design:

This is an open-label, single center phase 2 study evaluating 18F-fluciclovine PET/CT imaging in up to 50 participants with multiple myeloma. Participants will be enrolled into one of two cohorts based on disease status; newly diagnosed multiple myeloma (NDMM) participants will be enrolled into Cohort 1 and relapsed refractory multiple myeloma (RRMM) participants will be enrolled into Cohort 2. All subjects will undergo an 18F-fluciclovine injection followed by a static whole-body PET/CT at three time points: Timepoint #1, Timepoint #2 (after induction for NDMM or at 6 months for RRMM) and Timepoint #3 (at progression or at 5 years). Results will be compared to 18F-FDG PET/CT imaging at those same timepoints.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: NCI Medical Oncology Referral Office
  • Número de teléfono: (240) 760-6050
  • Correo electrónico: ncimo_referrals@nih.gov

Copia de seguridad de contactos de estudio

  • Nombre: Elizabeth M Hill, M.D.
  • Número de teléfono: (240) 889-5377
  • Correo electrónico: elizabeth.hill@nih.gov

Ubicaciones de estudio

    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • Reclutamiento
        • National Institutes of Health Clinical Center
        • Contacto:
          • NCI Medical Oncology Referral Office
          • Número de teléfono: 240-760-6050
          • Correo electrónico: ncimo_referrals@nih.gov

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 120 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

  • INCLUSION CRITERIA:

  • Participants must have a documented diagnosis of MM defined by the IMWG Criteria. Participants at diagnosis must have had a serum M-protein >= 3 g/dL and/or bone marrow plasma cells >= 10% and at least one of the following:

    • Anemia: Hemoglobin <=10 g/dL, or
    • Renal Failure: serum creatinine >= 2.0 mg/dL, or
    • Hypercalcemia: Ca >= 10.5 mg/dL, or
    • Lytic bone lesions on X-ray, CT, or PET/CT, or
    • >= 2 focal lesions on spinal MRI, or
    • >= 60% bone marrow plasma cells, or
    • Involved/un-involved serum free light chain ration >= 100
  • Participants must have measurable disease defined by any one of the following:

    • Monoclonal bone marrow plasma cells > 5%
    • Serum monoclonal protein >= 0.2 g/dl
    • Urine monoclonal protein > 200 mg/24 hr
    • Serum immunoglobulin free light chain > 10 mg/dL AND abnormal kappa/lambda ratio
    • A measurable lesion on PET/CT or MRI
  • Participants fit criteria for one of the following categories:

    • Newly diagnosed multiple myeloma (NDMM)
    • Relapsed and/or refractory multiple myeloma (RRMM) with at least 1 prior line of therapy
  • Age >=18 years.

  • ECOG performance status <= 2

  • Negative serum or urine pregnancy test at screening for WOCBP.

  • Women of child-bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control; abstinence) 24 hours prior to and for the 24 hours after each 18F-fluciclovine administration.

  • Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FDG
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-fluciclovine or other similar agents.
  • Subjects with severe claustrophobia unresponsive to oral anxiolytics or unwilling to take them.
  • Uncontrolled intercurrent illness including, psychiatric illness/social situations that would limit compliance with study requirements.
  • Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 18F-fluciclovine, breastfeeding should be discontinued if the mother is treated with 18F-fluciclovine until 3 days after 18F-fluciclovine.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: 18F-fluciclovine PET/CT in Multiple Myeloma

Evaluate 18F-fluciclovine PET/CT in participants with multiple myeloma at Timepoint #1, Timepoint #2 ( after induction treatment (NDMM) or six months (RRMM)) and at Timepoint #3 (the time of progression or 5 years).

370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.

All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To determine the concordance between 18F-fluciclovine PET/CT and 18F-FDG PET/CT in participants with multiple myeloma.
Periodo de tiempo: After 50 evaluable participants have completed baseline scans.

The performance of 18F-fluciclovine PET/CT is assessed by concordance with the 18F-FDG PET/CT imaging in scan positivity. A positive lesion is defined as focal uptake greater than background associated with abnormal CT findings (i.e., lytic bone lesions or extramedullary tissue.) The point estimates and 95% confidence intervals of the concordance rate in scan positivity between 18F-fluciclovine and 18F-FDG PET/CT will be reported.

After 50 evaluable participants have completed baseline scans.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Evaluate the efficacy of 18F-fluciclovine in measuring disease volume as compared to other indicators of disease volume such as serum M protein, serum free-light chains, urine M protein, B2 microglobulin, and bone marrow plasma cell percentage.
Periodo de tiempo: Between Timepoint #1 and Timepoint #3

Disease volumes measured by 18F-fluciclovine will be correlated with other indicators of disease volume such as serum M protein, serum free-light chains, urine M protein, B2 microglobulin, and bone marrow plasma cell percentage by Spearman rank correlation.

Between Timepoint #1 and Timepoint #3
Evaluate the ability of 18F-fluciclovine to identify minimal residual disease (MRD) as compared to MRD status determined by bone marrow flow cytometry or next generation sequencing (NGS).
Periodo de tiempo: Between Timepoint #1 and Timepoint #3

Status of minimal residual disease (MRD) identified by 18F-fluciclovine will be compared to MRD status determined by bone marrow flow cytometry or next generation sequencing (NGS).

Between Timepoint #1 and Timepoint #3
Evaluate the ability for 18F-fluciclovine to evaluate response after treatment as compared to the IMWG response criteria.
Periodo de tiempo: Between Timepoint #1 and Timepoint #3

Response after treatment determined by 18F-fluciclovine will be compared to the IMWG response criteria by McNemar test.

Between Timepoint #1 and Timepoint #3
Evaluate the safety of 18F-fluciclovine as a radiotracer in patients with multiple myeloma.
Periodo de tiempo: From the time at each 18F-fluciclovine dose through 3 days after each dose.

All participants will be evaluable for toxicity from the time at each 18F-fluciclovine dose through 3 days after each dose. Safety of the agents will be assessed by determining the type, grade, and frequency of adverse events noted in each participant who receives at least one dose of each of the study treatments. Safety data will be presented in a summary.

From the time at each 18F-fluciclovine dose through 3 days after each dose.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Elizabeth M Hill, M.D., National Cancer Institute (NCI)

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de marzo de 2024

Finalización primaria (Estimado)

6 de diciembre de 2027

Finalización del estudio (Estimado)

6 de diciembre de 2032

Fechas de registro del estudio

Enviado por primera vez

26 de octubre de 2023

Primero enviado que cumplió con los criterios de control de calidad

26 de octubre de 2023

Publicado por primera vez (Actual)

27 de octubre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

13 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All collected IPD will be shared. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

Marco de tiempo para compartir IPD

Clinical data will be made available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

Criterios de acceso compartido de IPD

Clinical data will be made available upon request and with the permission of the study PI. Genomic data are made available via dbGAP through requests to the data custodians.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir